Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Check out the latest renal regulatory news, clinical trial data, and nephrology research in this July 2025 recap.

6 Nephrology Headlines You Missed in July 2025

Recent FDA approvals of pegcetacoplan and iptacopan revolutionize C3 glomerulopathy treatment, offering hope and targeted options for patients.

Pegcetacoplan's Approval & Shifting C3G Landscape, with Sayna Norouzi, MD

C3G treatment options expand with FDA approvals of pegcetacoplan and iptacopan, offering new hope for patient care.

Pegcetacoplan's Approval and Shifting C3G Landscape, with Sayna Norouzi, MD

FDA approves pegcetacoplan (Empaveli) for treating C3 glomerulopathy and primary IC-MPGN, offering hope for patients aged 12 and older.

FDA Approves Pegcetacoplan (Empaveli) for C3 Glomerulopathy, IC-MPGN

The Q2 recap for nephrology spotlights key FDA decisions and top coverage from the 62nd European Renal Association Congress.

Q2 2025 Recap: Nephrology News and Updates

From new data for potential IgAN treatments to the use of combination initiation therapy for type 2 diabetes and CKD, here are 5 key updates from the annual meeting.

HCPLive Five at European Renal Association (ERA) Congress 2025

Panelists discuss how the complexity of diagnosing C3 glomerulopathy (C3G), the need for long-term treatment options, and the importance of addressing unmet needs, including the psychological impact on patients and families, highlights the challenges and future directions in improving care for these individuals.

Treating the Whole Patient: Addressing the Broader Unmet Needs in C3G Management

Panelists discuss how patient history, vaccination status, and risk of infection influence the decision to administer complement inhibitors, with some expressing caution in high-risk cases, particularly in pediatric populations with prior infections or low immunoglobulin levels.

Balancing Complement Inhibition and Infection Risk in C3G Treatment

A recap of 5 studies to know from the ERA 2025 Congress, including expert perspectives. 

ERA 2025 Recap: 5 Studies to Know

An analysis of the VALIANT trial provides insight into the benefits of pegcetacoplan in patients with C3G and IC-MPGN. 

Pegcetacoplan Could Halt Disease Progression in C3 Glomerulopathy, IC-MPGN, with Daniel Gale, PhD, MB BChir

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.